Quick Dispatch:
Your tirzepatide cvot trial SURPASS-CVOT trial: Tirzepatide was non-inferior to dulaglutide and superior to putative placebo for reducing the composite of CV death/HF events in patients with T2D and ASCVD. #AHA25 View the slides here: https://t.co/6VQpBHFP2I orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your tirzepatide cvot trial SURPASS-CVOT trial: Tirzepatide was non-inferior to dulaglutide and superior to putative placebo for reducing the composite of CV death/HF events in patients with T2D and ASCVD. #AHA25 View the slides here: https://t.co/6VQpBHFP2I ships.
Need Help?
Questions about tirzepatide cvot trial SURPASS-CVOT trial: Tirzepatide was non-inferior to dulaglutide and superior to putative placebo for reducing the composite of CV death/HF events in patients with T2D and ASCVD. #AHA25 View the slides here: https://t.co/6VQpBHFP2I, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for tirzepatide cvot trial SURPASS-CVOT trial: Tirzepatide was non-inferior to dulaglutide and superior to putative placebo for reducing the composite of CV death/HF events in patients with T2D and ASCVD. #AHA25 View the slides here: https://t.co/6VQpBHFP2I in your area.
In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%
29.71
Frontiers
22.71
AHA 25: SURPASS-CVOT: Tirzepatide vs Dulaglutide for Heart Failure in T2D
20.83
Frontiers
23.68
Tirzepatide in SURPASS‑CVOT: Favorable Cardiovascular Outcomes in Type 2 Diabetes
29.57
SURPASS-CVOT Shows Mounjaro Surpasses Trulicity in CV Outcomes
20.16
Diabetes Dialogue: Tirzepatide and SURPASS-CVOT Topline Results
22.60
